Australian Pharmaceutical Patents Expiring November 2013

Below is a report from IP Organisers (an independent service company of Phillips Ormonde Fitzpatrick) detailing Australian Pharmaceutical Patents which will expire in the next month.

ip org 

Australian Pharmaceutical Patents

Expiring November 2013

DIOVAN Valsartan
Chemical Name N-Pentanoyl-N-[2’-(1H-tetrazol-5-yl)biphenyl-4ylmethyl]-L-valine
Chemical Structure  1
Australian Patent AU-B2-644844
Expiry Date 19 November 2013
Patent Assignee Novartis AG
Title Biphenylylaliphathylamino compounds, their use as antihypertensives, pharmaceutical compositions and processes for their manufacture
Abstract Aromatic amide derivatives of 2formula  and their salts are new. (Where R1 = aliphatic hydrocarbon optionally substituted with halogen or OH, or a cycloaliphatic or araliphatic hydrocarbon. X1 = CO, SO2, or OCO with the carbon linked to the N. X2 = aliphatic hydrocarbon (optionally substituted with OH, carboxy, NH2, guanidino, cycloaliphatic or aromatic hydrocarbon) or cycloaliphatic hydrocarbon, with a carbon of the aliphatic optionally bridged by a divalent aliphatic hydrocarbon. R2 = carboxy or its ester or amide derivative, NH2, substituted amino, formyl, acetal derivative of formyl, 1H-tetrazol-5-yl, pyridyl, OH, ether, SR, SOR, SO2R, alkanoyl, sulphamoyl, N-substituted sulphamoyl, PO2H2 or PO3H2. R = H or aliphatic hydrocarbon. X3 = hydrocarbon. R3 = carboxy, 5-tetrazolyl, SO3H, PO2H2, PO3H2 or haloalkylsulphamoyl.; Rings A and B are each optionally substd. 121 compounds are specifically claimed, including (S)-N-(1-carboxy -2-methyl)-prop-1-yl) -N-pentanoyl-N- (2′-(1H-tetrazol-5-yl) biphenyl-4-ylmethyl) amine.
Australian Register of Therapeutic Goods ARTG ID 123357
Consumer Medicine Information DIOVAN (Valsartan)
Product Information DIOVAN (Valsartan)
ROTATEQ Rotavius
Chemical Name rotavirus vaccine, live, oral, pentavalent, MSD
Chemical Structure
Australian Patent AU-B2-618973
Expiry Date 28 November 2013
Patent Assignee The Wistar Institute of Anatomy and BiologyThe Children’s Hospital Foundation
Title Novel rotavirus reassortant vaccine
Abstract The present invention provides novel rotavirus reassortants, vaccines employing the novel reassortants and methods for their preparation and administration. The reassortant contains at least the gene encoding the vp3 neutralization antigen of bovine rotavirus of the WC3 strain and the gene encoding the vp7 neutralization antigen of a selected human rotavirus.
Australian Register of Therapeutic Goods ARTG ID 120245
Consumer Medicine Information ROTATEQ
Product Information ROTATEQ
AZELASTINE HYDROCHLORIDE Azelastine Hydrochloride Nasal Spray Formulation
Chemical Name (RS)-4-[(4-chlorophenyl)methyl]-2- (1-methylazepan-4-yl)-phthalazin-1-one Hydrochloride
Chemical Structure  3
Australian Patent AU-B2-613107
Expiry Date 11 November 2013
Patent Assignee MEDA Pharma GmbH & Co. KG
Title Azelastine-containing medicaments for application in the nose and/or at the eye
Abstract A medicament for nasal application or for application to the eye and/or the nose which contains 0.0005 to 2% (weight/weight) of azelastine or a physiologically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent and/or adjuvant. A medicament according to claim 1 characterized in that it is used for the treatment of allergy-related, or vasomotor or rhino virus-related colds or symptoms.
Australian Register of Therapeutic Goods ARTG ID 104853
Consumer Medicine Information AZEP Nasal Spray
Product Information

For further information please contact Rodney Chiang-Cruise or Aaron McMillan at IP Organisers Pty Ltd

IP Organisers is an Australian company specialising in the provision of intellectual property support services to Australian and international companies, organisations and professional services firms.